Sleep apnea is a sleep-related breathing disorder characterized by repeated episodes of complete or partial upper-airway collapse during sleep, leading to oxygen desaturation and sleep fragmentation. It causes nonrestorative sleep and daytime impairment, and has important cardiometabolic and neurocognitive consequences.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Soon-to-be brides and grooms in India are increasingly seeking Mounjaro and other weight-loss injections before weddings, with doctors reporting rising demand. The trend comes as India’s obesity-drug market expands, cheaper semaglutide versions enter the market, and regulators raise misuse concerns.
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
The FDA announced plans to restrict GLP-1 active pharmaceutical ingredients for compounded drugs and combat misleading advertising, following the Trump administration's launch of TrumpRx and ongoing enforcement actions against compounding pharmacies.
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07465874 |
Validity and Reliability of the 6-Minute Pegboard and Ring Test (6PBRT) in Adults With Obstructive Sleep Apnea Syndrome |
NOT_YET_RECRUITING | |
| NCT07332442 |
Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea |
RECRUITING | PHASE3 |
| NCT07243405 |
Neurostimulation for Sleep Disordered Breathing (SDB) |
RECRUITING | NA |
| NCT07207473 |
Behavioral Optimization to Overcome Obstructive Sleep Apnea Treatment Barriers |
NOT_YET_RECRUITING | NA |
| NCT07136272 |
Detection of Sleep Stages and Arousals Using Neural Network Classifiers |
NOT_YET_RECRUITING | NA |
| NCT07124975 |
Impact of Comparing Treatment Status With Other CPAP Users |
ENROLLING_BY_INVITATION | NA |
| NCT07095413 |
Assessing the Performance of Wesper Lab for Obstructive and Central Sleep Apnea |
NOT_YET_RECRUITING | NA |
| NCT07086742 |
Validation of the Smart Mask V1 System and Its Measurements of SpO2 and Pulse Rate |
RECRUITING | NA |
| NCT06931028 |
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 |
RECRUITING | PHASE3 |
| NCT06915077 |
Personalised Treatment for OSA |
ENROLLING_BY_INVITATION |
